Patent intelligence · US
US 12102637
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
Patent details — US 12102637
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 1, 2024
- Expiration
- Sep 26, 2044
- Applicant
- Neurocrine Biosciences, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/513, A61K9/1611, A61K9/1623
Quick answer
US 12102637 (Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis) is held by Neurocrine Biosciences, Inc.. Status: granted. Granted Oct 1, 2024. Expires Sep 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Neurocrine Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/513, A61K9/1611, A61K9/1623, A61K9/1652, A61K9/2009
More from Neurocrine Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421193
GPR52 modulators and methods of use
granted -
US 12383536
CRF receptor antagonists and methods of use
granted -
US 12128033
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
granted -
US 12083227
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 11730739
Treatment of congenital adrenal hyperplasia
granted -
US 11718618
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
granted -
US 11713324
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
granted
Frequently asked questions
What is US patent 12102637?
US 12102637 (Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis) is held by Neurocrine Biosciences, Inc.. Status: granted. Granted Oct 1, 2024. Expires Sep 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12102637?
Neurocrine Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 111 pharmaceutical patents for this assignee.
When does US 12102637 expire?
Our index shows an expiration date of Sep 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.